The pharmaceutical industry constantly seeks efficient and reliable synthetic pathways for drug development. Among the vital components in this process are specialized chemical intermediates. One such compound is 4-(2,2-Dichlorocyclopropyl)phenol 1-acetate (CAS 144900-34-5), a chemical building block particularly important in the synthesis of hypolipidemic agents. For R&D scientists and procurement specialists, understanding its significance and securing a dependable supply is crucial for advancing cardiovascular health treatments.

Key Intermediate for Hypolipidemic Agents

4-(2,2-Dichlorocyclopropyl)phenol 1-acetate is recognized for its role as an intermediate in the production of Ciprofibrate. Ciprofibrate belongs to the fibrate class of drugs, which are primarily used to lower elevated levels of triglycerides and cholesterol in the blood. By targeting lipid metabolism, these drugs play a significant role in managing cardiovascular disease risk. The specific structural features of 4-(2,2-Dichlorocyclopropyl)phenol 1-acetate make it an ideal precursor, contributing the necessary dichlorocyclopropyl moiety to the final active pharmaceutical ingredient (API). If your formulation requires this specific structure, identifying a manufacturer with expertise in this intermediate is essential.

Procurement Considerations: Quality and Availability

When you need to buy 4-(2,2-Dichlorocyclopropyl)phenol 1-acetate for pharmaceutical manufacturing, quality and consistent availability are paramount. Sourcing this intermediate typically involves working with chemical manufacturers who specialize in complex organic synthesis. Key specifications to look for include high purity levels (often above 95%), accurate CAS number (144900-34-5), and a clear understanding of its physical properties, such as its appearance as a nearly white crystalline powder. Many pharmaceutical companies prefer to purchase from suppliers in China, given the robust chemical manufacturing infrastructure and competitive pricing. When requesting a quote, it’s advisable to inquire about bulk purchase options and any custom synthesis capabilities the supplier might offer.

The Synthesis Process and Supplier Network

The preparation of 4-(2,2-Dichlorocyclopropyl)phenol 1-acetate itself involves multi-step organic synthesis. Manufacturers leverage various chemical reactions to construct the complex molecular structure. For end-users, understanding the source of raw materials and the manufacturing process can provide added confidence in the product's quality. A well-established supplier network is indicative of a manufacturer's commitment to the pharmaceutical supply chain. When you decide to purchase this intermediate, seeking out suppliers who can provide detailed documentation, including certificates of analysis (CoA) and safety data sheets (SDS), is a standard practice.

Market Trends and Future Outlook

The demand for effective hypolipidemic agents continues to grow as awareness of cardiovascular health increases globally. Consequently, the demand for key intermediates like 4-(2,2-Dichlorocyclopropyl)phenol 1-acetate is expected to remain strong. Pharmaceutical companies looking to secure their supply chain might consider long-term contracts with reputable manufacturers. This ensures a stable source of this critical building block, supporting the consistent production of life-saving medications. If your company is involved in the development or production of Ciprofibrate or similar compounds, securing a reliable supplier for this intermediate is a strategic imperative.

In summary, 4-(2,2-Dichlorocyclopropyl)phenol 1-acetate is a vital component in the pharmaceutical synthesis of hypolipidemic drugs. Its procurement requires a focus on quality, purity, and supplier reliability. For businesses seeking to buy this essential intermediate, engaging with experienced manufacturers and suppliers will ensure the smooth progression of their drug development and manufacturing processes.